Q1 Earnings Estimate for MLTX Issued By HC Wainwright

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Equities researchers at HC Wainwright issued their Q1 2027 earnings estimates for shares of MoonLake Immunotherapeutics in a research note issued to investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.70) for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q2 2027 earnings at ($0.82) EPS, Q3 2027 earnings at ($0.91) EPS and Q4 2027 earnings at ($0.67) EPS.

Other equities analysts also recently issued reports about the company. Oppenheimer upped their price target on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. UBS Group set a $24.00 target price on MoonLake Immunotherapeutics in a research note on Friday, January 9th. Needham & Company LLC upped their target price on MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. Wolfe Research upgraded MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and increased their price target for the company from $12.00 to $24.00 in a research note on Monday, March 23rd. Finally, Royal Bank Of Canada raised their price target on MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the stock a “sector perform” rating in a report on Monday, March 2nd. Nine analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $23.08.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX opened at $16.93 on Tuesday. The company has a 50 day moving average of $16.87 and a two-hundred day moving average of $17.13. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -4.81 and a beta of 1.20.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.92) EPS for the quarter, hitting the consensus estimate of ($0.92). During the same quarter in the prior year, the business posted ($0.72) EPS.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Large investors have recently bought and sold shares of the company. Cormorant Asset Management LP raised its position in MoonLake Immunotherapeutics by 118.4% during the 4th quarter. Cormorant Asset Management LP now owns 4,355,433 shares of the company’s stock worth $57,405,000 after buying an additional 2,361,260 shares during the last quarter. Janus Henderson Group PLC lifted its stake in MoonLake Immunotherapeutics by 18,782.8% during the 4th quarter. Janus Henderson Group PLC now owns 2,095,988 shares of the company’s stock valued at $27,657,000 after acquiring an additional 2,084,888 shares during the period. Logos Global Management LP purchased a new stake in shares of MoonLake Immunotherapeutics in the 4th quarter valued at $23,065,000. Alliancebernstein L.P. boosted its holdings in shares of MoonLake Immunotherapeutics by 17.8% in the 2nd quarter. Alliancebernstein L.P. now owns 1,138,022 shares of the company’s stock valued at $53,715,000 after acquiring an additional 171,932 shares during the last quarter. Finally, Vivo Capital LLC acquired a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter worth $13,180,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.